Метаболические фенотипы старческой астении и течение сахарного диабета 2 типа

Распространенность сахарного диабета (СД) увеличивается с возрастом. В настоящее время синдром старческой астении (ССА, хрупкость) у больных СД 2 типа считается дополнительным осложнением к традиционным микро- и макрососудистым. ССА вызывает изменения состава тела и метаболизма, формируя определенные фенотипы, которые влияют на течение СД 2 типа, выбор целевых показателей гликемии и сахароснижающей терапии. Анализу метаболических изменений и фенотипов, связанных с ССА, их влиянию на течение СД 2 типа, выбор сахароснижающей терапии и целевых значений гликемии посвящена данная статья.

сахарный диабет, синдром старческой астении, пожилые люди, сахароснижающая терапия, гликемия

1. Sun H., Saeedi P., Karuranga S. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pr. 2021, 183. doi: 10.1016/j.diabres.2021.109119.

2. Assar M.E., Laosa O., Rodríguez Mañas L. Diabetes and frailty. Curr. Opin. Clin. Nutr. Metab Care. 2019;22:52-57. doi: 10.1097/MCO.0000000000000535.

3. Tkacheva O.N., Kotovskaya Yu.V., Runikhina N.K. et al. Clinical guidelines on frailty.Russian Journal of Geriatric Medicine. 2020;(1):11-46. (In Russ.) doi: 10.37586/2686-8636-1-2020-11-46.@@ Ткачева О.Н., Котовская Ю.В., Рунихина Н.К. и др. Клинические рекомендации «Старческая астения». Российский журнал гериатрической медицины. 2020;(1):11-46. doi: 10.37586/2686-8636-1-2020-11-46.

4. Chhetri J.K., Zheng Z., Xu X. et al. The prevalence and incidence of frailty in Pre-diabetic and diabetic communitydwelling older population: Results from Beijing longitudinal study of aging II (BLSA-II). BMC Geriatr. 2017;17:1-8. doi: 10.1186/s12877-017-0439-y.

5. Abdelha z A.H., Emmerton D., Sinclair A.J. Impact of frailty metabolic phenotypes on the management of older people with type 2 diabetes mellitus. Geriatr. Gerontol.Int. 2021, 21, 614-622. doi: 10.1111/ggi.14214.

6. American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45: S195-S207. doi: 10.2337/dc22-S013.

7. Sinclair A.J., Abdelha z A., Dunning T. et al. An International Position Statement on the Management of Frailty in Diabetes Mellitus: Summary of Recommendations 2017. J. Frailty Aging. 2018;7:10-20. doi: 10.14283/jfa.2017.39.

8. Dedov I., Shestakova M., Mayorov A. Et al. Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A. Yu. 11th Edition. Diabetes mellitus. 2023;26(2S):1-157. (In Russ.) doi: 10.14341/DM13042.@@ Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(2S):1-157. doi: 10.14341/DM13042.

9. García-Esquinas E., Graciani A., Guallar-Castillón P. et al. Diabetes and Risk of Frailty and Its Potential Mechanisms: A Prospective Cohort Study of Older Adults. J. Am. Med. Dir. Assoc. 2015;16:748-754. doi: 10.1016/j.jamda.2015.04.008.

10. Howrey B.T., Al Snih S., Markides K.S., Ottenbacher K.J. Frailty and diabetes among Mexican American older adults. Ann. Epidemiology. 2018;28:421-426.e1. doi: 10.1016/j.annepidem.2018.04.009.

11. Chao C.T., Wang J., Huang J.W. et al. Hypoglycemic episodes are associated with an increased risk of incident frailty among new onset diabetic patients. J. Diabetes Its Complicat. 2019;34:107492. doi: 10.1016/j.jdiacomp.2019.107492.

12. Ntouva A., AToulis K., Keerthy D. et al. Hypoglycaemia is associated with increased risk of fractures in patients with type 2 diabetes mellitus: A cohort study. Eur. J. Endocrinol. 2019;180:51-58. doi: 10.1530/EJE-18-0458.

13. MacKenzie H.T., Tugwell B., Rockwood K., Theou O. Frailty and Diabetes in Older Hospitalized Adults: The Case for Routine Frailty Assessment. Can. J. Diabetes. 2020;44:241-245.e1. doi: 10.1016/j.jcjd.2019.07.001.

14. Morita T., Okuno T., Himeno T. et al. Glycemic control and disability-free survival in hypoglycemic agent-treated community-dwelling older patients with type 2 diabetes mellitus. Geriatr. Gerontol.Int. 2017;17:1858-1865. doi: 10.1111/ggi.12975.

15. Zaslavsky O., Walker R.L., Crane P.K. et al. Glucose Levels and Risk of Frailty. J. Gerontol. Ser. A 2016;71:1223-1229. doi: 10.1093/gerona/glw024.

16. Rogers S.C., Zhang X., Azhar G. et al. Exposure to High or Low Glucose Levels Accelerates the Appearance of Markers of Endothelial Cell Senescence and Induces Dysregulation of Nitric Oxide Synthase. J. Gerontol. Ser. A 2013;68:1469-1481. doi: 10.1093/gerona/glt033.

17. Peng X., Ge J., Wang C. et al. Longitudinal Average Glucose Levels and Variance and Risk of Stroke: A Chinese Cohort Study.Int J Hypertens. 2020 Apr 21;2020:8953058. doi: 10.1155/2020/8953058.

18. Veronese N., Stubbs B., Fontana L. et al. Frailty Is Associated with an Increased Risk of Incident Type 2 Diabetes in the Elderly. J. Am. Med. Dir. Assoc. 2016;17:902-907. doi: 10.1016/j.jamda.2016.04.021.

19. Bulgakovа S.V., Chetverikova I.S., Treneva E.V., Kurmaev D.P. Senior asthenia and type 2 diabetes: two related conditions? Clinical gerontology. 2022;28(3-4):60-67. (in Russ.) doi: 10.26347/1607-2499202203-04060-067.@@ Булгакова С.В., Четверикова И.С., Тренева Е.В., Курмаев Д.П. Старческая астения и сахарный диабет типа 2: два взаимосвязанных состояния? Клиническая геронтология. 2022;28(3-4):60-67. doi: 10.26347/1607-2499202203-04060-067.

20. Kurmaev D.P., Bulgakova S.V., Treneva E.V. Insulin resistance, type 2 diabetes mellitus and sarcopenia. Experimental and Clinical Gastroenterology. 2024;(2):141-148. (In Russ.) doi: 10.31146/1682-8658-ecg-222-2-141-148.@@ Курмаев Д.П., Булгакова С.В., Тренева Е.В. Инсулинорезистентность, сахарный диабет 2 типа и саркопения. Экспериментальная и клиническая гастроэнтерология. 2024;(2):141-148. doi: 10.31146/1682-8658-ecg-222-2-141-148.

21. Choi K.M. Sarcopenia and sarcopenic obesity. Korean J.Intern. Med. 2016;31:1054-1060. doi: 10.3904/kjim.2016.193.

22. Kurmaev DP, Bulgakova SV, Treneva EV, et al. Physical training in a comprehensive program of prevention and treatment of sarcopenia in geriatric patients. Experimental and clinical gastroenterology. 2024;8(228):226-241. (In Russ.) doi: 10.31146/1682-8658-ecg-228-8-226-241.@@ Курмаев Д.П., Булгакова С.В., Тренева Е.В. и др. Физические тренировки в комплексной программе профилактики и лечения саркопении у гериатрических пациентов. Экспериментальная и клиническая гастроэнтерология. 2024;8(228):226-241. doi: 10.31146/1682-8658-ecg-228-8-226-241.

23. Cartwright M.J., Tchkonia T., Kirkland J.L. Aging in adipocytes: Potential impact of inherent, depot-speci c mechanisms. Exp. Gerontol. 2007;42:463-471. doi: 10.1016/j.exger.2007.03.003.

24. Szoke E., Shrayyef M.Z., Messing S. et al. Effect of aging on glucose homeostasis: Accelerated deterioration of β-cell function in individuals with impaired glucose tolerance. Diabetes Care. 2008;31:539-543. doi: 10.2337/dc07-1443.

25. Kim W., Egan J.M. The Role of Incretins in Glucose Homeostasis and Diabetes Treatment. Pharm. Rev. 2008;60:470-512. doi: 10.1124/pr.108.000604.

26. Bulgakova S., Romanchuk N., Treneva E. Glucagon-like Peptide 1, Brain, Neurodegenerative Diseases: A Modern View. Bulletin of Science and Practice. 2020;6(4):153-172. 6(4), 153-172. (in Russ.) doi: 10.33619/2414-2948/53/19.@@ Булгакова С.В., Романчук Н.П., Тренева Е.В. Глюкагоноподобный пептид 1, головной мозг, нейродегенеративные заболевания: современный взгляд. Бюллетень науки и практики. 2020;6(4):153-172. doi: 10.33619/2414-2948/53/19.

27. Schaap L.A., Pluijm S.M.F., Smit J.H. et al. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin. Endocrinol. 2005;63:152-160. doi: 10.1111/j.1365-2265.2005.02315.x.

28. Bulgakova S.V., Treneva E.V., Zaharova N.O., Nikolaeva A.V. The endocrine system and aging of the human body (review of the literature). Clinical gerontology. 2020;7-8:51-56. (In Russ.) doi: 10.26347/1607-2499202007-08051-056.@@ Булгакова С.В., Тренева Е.В., Захарова Н.О., Николаева А.В. Эндокринная система и старение организма человека (обзор дитературы). Клиническая геронтология. 2020;7-8:51-56. doi: 10.26347/1607-2499202007-08051-056.

29. Kim G., Kim J.H. Impact of Skeletal Muscle Mass on Metabolic Health. Endocrinol. Metab. 2020;35:1-6. doi: 10.3803/EnM.2020.35.1.1.

30. Horton W.B., Barrett E.J. Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease. Endocr. Rev. 2020;42:29-55. doi: 10.1210/endrev/bnaa025.

31. Gaulton K.J., Ferreira T., Lee Y. et al. DI-Abetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Genetic ne mapping and genomic annotation de- nes causal mechanisms at type 2 diabetes susceptibility loci. Nat. Genet. 2015;47:1415-1425. doi: 10.1038/ng.3437.

32. Skyler J.S., Bakris G.L., Bonifacio E. et al. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017;66:241-255. doi: 10.2337/db16-0806.

33. Bennasar-Veny M., Fresneda S., López-González A. et al. Lifestyle and Progression to Type 2 Diabetes in a Cohort of Workers with Prediabetes. Nutrients. 2020;12(5):1538. doi: 10.3390/nu12051538.

34. Abdelhafiz A.H., Keegan G.L., Sinclair A.J. Metabolic Characteristics of Frail Older People with Diabetes Mellitus-A Systematic Search for Phenotypes. Metabolites. 2023;13(6):705. doi: 10.3390/metabo13060705.

35. Sonjak V., Jacob K., Morais J.A. et al. Fidelity of muscle bre reinnervation modulates ageing muscle impact in elderly women. J. Physiol. 2019;597:5009-5023. doi: 10.1113/JP278261.

36. St-Jean-Pelletier F., Pion C.H., Leduc-Gaudet J-P. et al. The impact of ageing, physical activity, and pre-frailty on skeletal muscle phenotype, mitochondrial content, and intramyocellular lipids in men. J. Cachexia Sarcopenia Muscle. 2017;8:213-228. doi: 10.1002/jcsm.12139.

37. Gates A.T., Kjaer M., Andersen J.L. One Year of Heavy Resistance Training Modifies Muscle Fiber Characteristics in the Elderly. Sports Med Int Open. 2024 Jul 20;8: a23388226. doi: 10.1055/a-2338-8226.

38. Miljkovic N., Lim J.Y., Miljkovic I., Frontera W.R. Aging of Skeletal Muscle Fibers. Ann. Rehabilitation Med. 2015, 39, 155-162. doi: 10.5535/arm.2015.39.2.155.

39. Abdelhafiz A.H., Sinclair A.J. Metabolic phenotypes explain the relationship between dysglycaemia and frailty in older people with type 2 diabetes. J Diabetes Complications. 2022;36(4):108144. doi: 10.1016/j.jdiacomp.2022.108144.

40. Watanabe D., Yoshida T., Watanabe Y. et al. A U-Shaped Relationship between the Prevalence of Frailty and Body Mass Index in Community-Dwelling Japanese Older Adults: The Kyoto-Kameoka Study. J. Clin. Med. 2020;9:1367. doi: 10.3390/jcm9051367.

41. Kurmaev D.P., Bulgakova S.V., Treneva E.V. Sarcopenic obesity - a current problem of modern geriatrics.Russian Journal of Geriatric Medicine. 2022;(4):228-235. (In Russ.) doi: 10.37586/2686-8636-4-2022-228-235.@@ Курмаев Д.П., Булгакова С.В., Тренева Е.В. Саркопеническое ожирение - актуальная проблема современной гериатрии. Российский журнал гериатрической медицины. 2022;(4):228-235. doi: 10.37586/2686-8636-4-2022-228-235.

42. El Bizri I., Batsis J.A. Linking epidemiology and molecular mechanisms in sarcopenic obesity in populations. Proc. Nutr. Soc. 2020;79:448-456. doi: 10.1017/S0029665120000075.

43. Chait A., den Hartigh L.J. Adipose Tissue Distribution, In ammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med. 2020;7:22. doi: 10.3389/fcvm.2020.00022.

44. Kurmaev D.P., Bulgakova S.V., Treneva E.V., Kosareva O.V., Dolgikh Yu.A., Sharonova L.A., Chetverikova I.S. Nutritional support in a comprehensive program of prevention and treatment of sarcopenia.Russian Journal of Geriatric Medicine. 2023;(1):29-38. (In Russ.) doi: 10.37586/2686-8636-1-2023-29-38.@@ Курмаев ДП, Булгакова СВ, Тренева ЕВ. и др. Нутритивная поддержка в комплексной программе профилактики и лечения саркопении. Российский журнал гериатрической медицины. 2023;1(13):29-38. doi: 10.37586/2686-8636-1-2023-29-38.

45. María Pérez-Sánchez C., Nicolás Torres D., Hernández Morante J.J. Altered Eating Attitudes in Nursing Home Residents and Its Relationship with their Cognitive and Nutritional Status. J Nutr Health Aging. 2018;22(7):869-875. doi: 10.1007/s12603-018-1056-y.

46. Batchelor-Murphy M., Kennerly S.M., Horn S.D., Barrett R., Bergstrom N., Boss L., Yap T.L. Impact of Cognition and Handfeeding Assistance on Nutritional Intake for Nursing Home Residents. J Nutr Gerontol Geriatr. 2019;38(3):262-276. doi: 10.1080/21551197.2019.1617221.

47. Campitelli M.A., Bronskill S.E., Hogan D.B. et al. The prevalence and health consequences of frailty in a population-based older home care cohort: A comparison of different measures. BMC Geriatr. 2016;16:1-10. doi: 10.1186/s12877-016-0309-z.

48. Goulet E.D., Hassaine A., Dionne I.J. et al. Frailty in the elderly is associated with insulin resistance of glucose metabolism in the postabsorptive state only in the presence of increased abdominal fat. Exp. Gerontol. 2009, 44, 740-744. doi: 10.1016/j.exger.2009.08.008.

49. Abdelha z A.H., Koay L., Sinclair A.J. The Emergence of Frailty May Lead to a State of Burnt Out Type 2 Diabetes. J. Frailty Aging. 2016, 5, 162-167. doi: 10.14283/jfa.2016.98.

50. Xia M.F., Chen L.Y., Wu L. et al. Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study. Clin. Nutr. 2020;40:571-580. doi: 10.1016/j.clnu.2020.06.003.

51. Cho H.W., Chung W., Moon S. et al. Effect of Sarcopenia and Body Shape on Cardiovascular Disease According to Obesity Phenotypes. Diabetes Metab. J. 2021;45:209-218. doi: 10.4093/dmj.2019.0223.

52. Hojs R., Ekart R., Bevc S., Vodošek Hojs N. Chronic Kidney Disease and Obesity. Nephron. 2023;147(11):660-664. doi: 10.1159/000531379.

53. García-Carro C., Vergara A., Bermejo S. et al. A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management. Front. Med. 2021;8:655871. doi: 10.3389/fmed.2021.655871.

54. Godoy-Matos A.F., Júnior W.S.S., Valerio C.M. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol. Metab. Syndr. 2020;12:1-20. doi: 10.1186/s13098-020-00570-y.

55. Abdelha z A.H., Sinclair A.J. Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy. J. Diabetes Its Complicat. 2020;34:107639. doi: 10.1016/j.jdiacomp.2020.107639.

56. Marsico F., Paolillo S., Gargiulo P. et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: A meta-analysis of randomized controlled trials. Eur. Heart J. 2020;41:3346-3358. doi: 10.1093/eurheartj/ehaa082.

57. Adingupu D.D., Göpel S.O., Grönros J. et al. SGLT2 inhibition with empagli ozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/-mice. Cardiovasc. Diabetol. 2019, 18, 1-15. doi: 10.1186/s12933-019-0820-6.

58. Bae J.H., Park E.G., Kim S. et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Sci. Rep. 2019;9:1-9. doi: 10.1038/s41598-019-49525-y.

59. Lv X., Dong Y., Hu L. et al. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol. Diabetes Metab. 2020, 3, e00163. doi: 10.1002/edm2.163.

60. Xing B., Zhao Y., Dong B. et al. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J. Diabetes Investig. 2020;11:1238-1247. doi: 10.1111/jdi.13237.

61. Emmerton D., Abdelha z A. Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people. Hosp. Pr. 2021;49:164-175. doi: 10.1080/21548331.2021.1905414.

62. Bollig C., Torbahn G., Bauer J. et al. Evidence gap on antihyperglycemic pharmacotherapy in frail older adults. Z. Fur Gerontol. Und Geriatr. 2020;54:278-284. doi: 10.1007/s00391-020-01724-3.

63. Liu H.M., Zhang Q., Shen W.D. et al. Sarcopenia-related traits and coronary artery disease: A bi-directional Mendelian randomization study. Aging (Albany NY). 2020;12:3340-3353. doi: 10.18632/aging.102815.

64. Villareal D.T., Aguirre L., Gurney A.B. et al. Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. N. Engl. J. Med. 2017;376:1943-1955. doi: 10.1056/NEJMoa1616338.

65. Wittmann K., Sieber C., von Stengel S. et al. Impact of whole body electromyostimulation on cardiometabolic risk factors in older women with sarcopenic obesity: the randomized controlled FORMOsA-sarcopenic obesity study. Clin Interv Aging. 2016;11:1697-1706. doi: 10.2147/CIA.S116430.

66. Kelly O.J., Gilman J.C. Can Unconventional Exercise be Helpful in the Treatment, Management and Prevention of Osteosarcopenic Obesity? Curr Aging Sci. 2017;10(2):106-121. doi: 10.2174/1874609809666160509122725.

67. Bulgakova S.V., Romanchuk P.I., Treneva E.V. Insulin, brain, alzheimer’s disease: new evidence. Bulletin of Science and Practice. 2020;6(3):96-126. doi: 10.33619/2414-2948/52/10.@@ Булгакова С.В., Романчук П.И., Тренева Е.В. Инсулин, головной мозг, болезнь Альцгеймера: новые данные. Бюллетень науки и практики. 2020;6(3):96-126. doi: 10.33619/2414-2948/52/10.

68. Ferrari U., Then C., Rottenkolber M. et al. Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the KORA-Age study. Acta Diabetol. 2020, 57, 1057-1063. doi: 10.1007/s00592-020-01523-7.

69. Sugimoto K., Ikegami H., Takata Y. et al. Glycemic Control and Insulin Improve Muscle Mass and Gait Speed in Type 2 Diabetes: The MUSCLES-DM Study. J. Am. Med. Dir. Assoc. 2021, 22, 834-838.e1. doi: 10.1016/j.jamda.2020.11.003.

70. Bradley M.C., Chillarige Y., Lee H. et al. Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin. JAMA Intern. Med. 2021;181:598. doi: 10.1001/jamainternmed.2020.9176.

71. Bulgakova S.V., Saverskaya E.N., Sharonova L.A., Dolgikh Y.A., Kosareva O.V. Biosimilar of analogue of insulin glargin: proven safety, effectiveness, interchangeability. Meditsinskiy sovet = Medical Council. 2022;(23):207-214. (In Russ.) doi: 10.21518/2079-701X-2022-16-23-207-214.@@ Булгакова С.В., Саверская Е.Н., Шаронова Л.А., Долгих Ю.A., Косарева О.В. Биосимиляр аналога инсулина гларгин: доказанная безопасность, эффективность, взаимозаменяемость. Медицинский совет. 2022;16(23):207-214. doi: 10.21518/2079-701X-2022-16-23-207-214.

72. Zçelik S., Çelik M., Vural A. et al. Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: A real-world experience. Arch. Med. Sci. 2021, 17, 1-8. doi: 10.5114/aoms.2020.93264.

73. Bahat G., Ozkok S., Petrovic M. Management of Type 2 Diabetes in Frail Older Adults. Drugs Aging. 2023 Sep;40(9):751-761. doi: 10.1007/s40266-023-01049-x.

74. Bulgakova S.V., Dolgikh Yu.A., Sharonova L.A., Kosareva O.V., Treneva E.V., Kurmaev D.P. Problems of choosing hypoglycemic therapy in elderly patients. Adv. geront. 2023;36(1):115-125. doi: 10.34922/AE.2023.36.1.015.@@ Булгакова С.В., Долгих Ю.А., Шаронова Л.А., Косарева О.В., Тренева Е.В., Курмаев Д.П. Проблемы выбора сахароснижающей терапии у пожилых пациентов (обзор литературы). Успехи геронтологии. 2023;36(1):115-125. doi: 10.34922/AE.2023.36.1.015.

75. Abdelha z A., Bisht S., Kovacevic I. et al. Insulin in Frail, Older People with Type 2 Diabetes - Low Threshold for Therapy. Diabetology. 2022;3:369-383. doi: 10.3390/diabetology3020028.

76. Rodriguez-Mañas L., Laosa O., Vellas B. et al. Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus. J. Cachex- Sarcopenia Muscle. 2019;10:721-733. doi: 10.1002/jcsm.12432.

77. Xiong X.F., Yang Y., Wei L. et al. Identification of two novel subgroups in patients with diabetes mellitus and their association with clinical outcomes: A two-step cluster analysis. J Diabetes Investig. 2021;12(8):1346-1358. doi: 10.1111/jdi.13494.

78. Monti G., Moreira D.G., Richner M. et al. GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells. 2022, 11, 2023. doi: 10.3390/cells11132023.

79. Dolgikh Yu.A., Bulgakova S.V., Kurmaev D.P., Treneva E.V., Kosareva O.V., Merzlova P. Ya., Sharonova L.A., Bulgakov A.S. Hypoglycemic drugs and sarcopenia. Experimental and Clinical Gastroenterology. 2024;(8):216-225. (In Russ.) doi: 10.31146/1682-8658-ecg-228-8-216-225.@@ Долгих Ю.А., Булгакова С.В., Курмаев Д.П., Тренева Е.В., Косарева О.В., Мерзлова П.Я., Шаронова Л.А., Булгаков А.С. Сахароснижающие препараты и саркопения. Экспериментальная и клиническая гастроэнтерология. 2024;8(228):216-225. doi: 10.31146/1682-8658-ecg-228-8-216-225.

80. Bajaj H.S., Bergenstal R.M., Christoffersen A. et al. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Diabetes Care. 2021;44:1586-1594. doi: 10.2337/dc20-2877.